Earnings Per Common Share Attributable to Common Shareholders (Tables)

6 Months Ended

Jun. 29, 2014

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Earning Per Share

The following table provides the detailed calculation of Earnings per common share (EPS):
	Three Months Ended				Six Months Ended
(IN MILLIONS)	June 29, 2014		June 30, 2013		June 29, 2014		June 30, 2013
EPS Numerator––Basic
Income from continuing operations	$	2,921	$	3,575	$	5,186	$	6,191
Less: Net income attributable to noncontrolling interests	9		10		18		19
Income from continuing operations attributable to Pfizer Inc.	2,912		3,565		5,168		6,172
Less: Preferred stock dividends––net of tax	1		—		1		1
Income from continuing operations attributable to Pfizer Inc. common shareholders	2,911		3,565		5,167		6,171
Discontinued operations––net of tax	—		10,559		73		10,708
Less: Discontinued operations––net of tax, attributable to noncontrolling interests	—		25		—		39
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders	—		10,534		73		10,669
Net income attributable to Pfizer Inc. common shareholders	$	2,911	$	14,099	$	5,240	$	16,840
EPS Numerator––Diluted
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions	$	2,912	$	3,565	$	5,168	$	6,172
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions	—		10,534		73		10,669
Net income attributable to Pfizer Inc. common shareholders and assumed conversions	$	2,912	$	14,099	$	5,241	$	16,841
EPS Denominator
Weighted-average number of common shares outstanding––Basic	6,368		7,042		6,379		7,115
Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock	76		75		81		70
Weighted-average number of common shares outstanding––Diluted	6,444		7,117		6,460		7,185
Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans(a)	44		44		44		44

^(a)  These common stock equivalents were outstanding for the six months ended June 29, 2014 and June 30, 2013, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.